Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

Inclusion Criteria: * Subjects will be females or males, smokers or non-smokers * 18 years of age and older * Subjects should read, sign and date an Informed Consent Form prior to any study procedures * Subjects must complete all screening procedures within 28 days prior to the administration of the study medication Exclusion Criteria: * Breast feeding female subjects * Clinically significant anormalities found during medical screening * Any clinically significant gastrointestinal pathology or unresolved gastrointestinal symptoms susceptible of interfering with the absorption of drugs * Clinically significant illnesses within 4 weeks of the administration of study medication * Abnormal laboratory tests judged clinically significant * ECG abnormalities or vital sign abnormalities at screening * Subjects with BMI greater than or equal to 30.0 * History of allergic reactions to cabergoline or ergot derivatives * Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in the study * Positive urine drug screen at screening * Positive testing for hepatitis B, hepatitis C or HIV at screening * Positive urine pregnancy test at screening (performed on all females) * Use of investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication * Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication * History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day * History of drug abuse or use of illegal drugs: use of soft drugs (marijuana, pot) within 3 months of the screening visit or hard drugs (cocaine, PCP, crack)within 1 year of the screening visit * Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic absorption * Female subjects of childbearing potential who have had unprotected sexual intercourse with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for at last 6 months) within 14 days prior to the study drug administration. The acceptable methods of contraception are condom + spermicide (at least 14 days prior to study drug administration), diaphragm + spermicide (at least 14 days prior to study drug administration)or intrauterine contraceptive device (placed at least 4 weeks prior to study drug administration * Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication * Subjects who have undergone clinically significant surgery within 4 weeks prior to the administration of the study medication * Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study